Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Teva
Chubb
Harvard Business School
QuintilesIMS
Deloitte

Generated: August 24, 2019

DrugPatentWatch Database Preview

EGATEN Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

When do Egaten patents expire, and what generic alternatives are available?

Egaten is a drug marketed by Novartis Pharms Corp and is included in one NDA.

The generic ingredient in EGATEN is triclabendazole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the triclabendazole profile page.

Summary for EGATEN
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 99
Patent Applications: 509
DailyMed Link:EGATEN at DailyMed
Drug patent expirations by year for EGATEN
Generic Entry Opportunity Date for EGATEN
Generic Entry Date for EGATEN*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for EGATEN
1H-BENZIMIDAZOLE, 5-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-
1H-Benzimidazole, 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-
4784C8E03O
5-[2,3-bis(chloranyl)phenoxy]-6-chloranyl-2-methylsulfanyl-1H-benzimidazole
5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole
5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole
5-chloro-6-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-1,3-benzodiazole
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-benzimidazole
6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole
6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole
6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole
6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazole
6-CHLORO-5-(2,3-DICHLOROPHENOXY)-2-METHYLTHIO-BENZ
6-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazole
6-chloro-5-(2,3-dichlorophenoxy)-2-methylthiobenzimidazole
68786-66-3
786T663
A3375/0143230
A836250
AB0013427
AB00639964_12
AB00639964_13
AB00639964-10
AB1004580
AC-7627
AC1L18Q8
AJ-26174
AK-68238
AKOS005439340
AKOS015950804
AN-8843
ANW-42745
API0004496
AX8034628
BDBM58491
BEN631
BR-68238
BRD-K81916719-001-05-5
C14H9Cl3N2OS
CAS-68786-66-3
CCG-100881
CCRIS 8988
CGA 89317
CGA-89317
CHEBI:94759
CHEMBL1086440
cid_50248
CJ-23547
CJ-23548
CPD000466357
CS-2859
CTK5C8452
D07364
DB12245
DSSTox_CID_23952
DSSTox_GSID_43952
DSSTox_RID_80094
DTXSID7043952
EGA230B
Fasinex
Fasinex (TN)
FT-0602564
HMS2051E16
HMS2232D14
HMS3370H02
HMS3393E16
HMS3652M16
HMS3715P16
HY-B0621
I018
I06-0122
KS-00000KPE
KS-5329
KUC103451N
LS-32758
MCULE-8131756770
MLS000759473
MLS000876812
MLS001424101
MolPort-000-705-689
MolPort-002-230-021
MP-0274
NC00131
NCGC00164610-01
NCGC00164610-02
NQPDXQQQCQDHHW-UHFFFAOYSA-N
NSC-759250
NSC759250
NVP-EGA230
Oprea1_236106
Pharmakon1600-01505786
s4114
SAM001246681
SB17173
SBI-0207022.P001
SC-17720
SCHEMBL165712
SMR000466357
SR-01000759363
SR-01000759363-4
ST2418930
STK332284
SW197511-2
TL8004821
Tox21_112231
TR-022940
Triclabendazol
Triclabendazol [INN-Spanish]
Triclabendazole
Triclabendazole (INN)
Triclabendazole [BAN:INN]
Triclabendazole [USAN:INN:BAN]
Triclabendazole for system suitability, EuropePharmacopoeia (EP) Reference Standard
Triclabendazole, 98%
Triclabendazole, EuropePharmacopoeia (EP) Reference Standard
Triclabendazole, VETRANAL(TM), analytical standard
Triclabendazolum
Triclabendazolum [INN-Latin]
UNII-4784C8E03O
ZINC1444556

US Patents and Regulatory Information for EGATEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp EGATEN triclabendazole TABLET;ORAL 208711-001 Feb 13, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Novartis Pharms Corp EGATEN triclabendazole TABLET;ORAL 208711-001 Feb 13, 2019 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Deloitte
Fuji
US Army
McKesson
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.